Blog, News, Companies, blood glucose meters, oral, Nasal, transdermal, insulin,type 2, pancreatic islet cells, Macular Edema, Ulcers, continuous glucose monitoring, HbA1c, hemoglobin A1C, oral anti-diabetic agent, data management system, Hypoglycemia, glucagon, therapeutic vaccine, peripheral neuropathy, Neuropathic pain, diabetes mellitus, type 1, foot ulcers, test strip, glycemic control, nephropathy, resistant, sensitizers, foot infections, sensor, retinopathy, non-invasive monitor...
Calif., Oct 09, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has received a $1.25 million milestone payment in the form of equity securities in iCo Therapeutics. The milestone was related to the initiation of Phase 1 clinical trials of iCo-007, a drug licensed to iCo by Isis in 2005 for the treatment of various eye diseases, including diabetic macular edema...
